The biopharmaceutical industry is experiencing a paradigm shift as advanced therapies such as mRNA-based drugs, cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), and bispecific antibodies gain momentum.

According to industry reports, the gene therapy market is poised to grow at a CAGR of 18.6% from 2022 to 2027. Similarly, the global bispecific antibody (BsAbs) therapeutics market is estimated to grow at a CAGR of 25.9% between 2022 and 2028. In the case of mRNAs, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialization.

Emerging and virtual firms, which represent the majority of the advanced biotherapeutic developers, are driving the future biopharma pipeline for these modalities. As a result, there has been a spike in demand for CDMOs with the expertise and capacity to work with new modalities.

This article explores what support biopharma companies are seeking from service providers and the challenges and hurdles before CDMOs themselves in bringing these novel therapies to market in the shortest possible time.

Learn about Syngene’s expertise in ADCs, CGTs, and mRNA-based therapies.